<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04303195</url>
  </required_header>
  <id_info>
    <org_study_id>NG101-201</org_study_id>
    <nct_id>NCT04303195</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis</brief_title>
  <official_title>A Phase 2 Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study, of the Safety and Efficacy of NG101 Administered Orally to Patients With Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurogastrx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurogastrx, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of various dose levels of
      NG101 compared with placebo in adult participants with gastroparesis during 12 weeks of
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, parallel-group , placebo-controlled, multicenter US-based
      study to evaluate the safety and efficacy of 3 dose levels of NG101 (Metopimazine) compared
      with placebo in participants with diabetic or idiopathic gastroparesis.

      The study will enroll approximately 280 participants. Following the Screening Period, there
      is a 2-week Pretreatment Period during which participants will complete an electronic daily
      diary. Participants eligible for the clinical study will be randomly assigned (in a 1:1:1:1
      ratio) to receive either NG101 5 mg, 10 mg, or 20 mg, or matching placebo during a 12-week
      Treatment Period. All participants will be asked to take one capsule 30 minutes before a meal
      3 times a day and 30 minutes before bedtime for a total of 4 capsules daily (QID). The total
      duration of the study for each participant will be approximately 20 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Severity of Nausea</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from Baseline at weeks 7 through12 as measured by patient's daily diary entries during participation in the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of Adverse Events</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Incidence and severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of Symptoms</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline at Weeks 7 through 12 as measured by patient's daily diary entries during participation in the study for number of discrete episodes of vomiting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of Symptoms</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline at Weeks 7 through 12 as measured by patient's daily diary entries during participation in the study for early satiety severity score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline at Weeks 7 through 12 as measured by patient's daily diary entries during participation in the study for postprandial fullness severity score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline at Weeks 7 through 12 as measured by patient's daily diary entries during participation in the study for abdominal pain severity score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline at Weeks 7 through 12 as measured by patient's daily diary entries during participation in the study for total severity score (nausea, early satiety, postprandial fullness, abdominal pain).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Diabetic Gastroparesis</condition>
  <condition>Idiopathic Gastroparesis</condition>
  <arm_group>
    <arm_group_label>NG101 - 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NG101 5 mg, capsules, orally, QID (4 times a day) for up to 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NG101 - 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NG101 10 mg, capsules, orally, QID (4 times a day) for up to 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NG101 - 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NG101 20 mg, capsules, orally, QID (4 times a day) for up to 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo-matching, capsules, orally, QID (4 times a day) for up to 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NG101</intervention_name>
    <description>Capsules</description>
    <arm_group_label>NG101 - 10 mg</arm_group_label>
    <arm_group_label>NG101 - 20 mg</arm_group_label>
    <arm_group_label>NG101 - 5 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>metopimazine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with diabetic or idiopathic gastroparesis

          -  Symptoms consistent with gastroparesis (nausea, vomiting, early satiety, post-prandial
             fullness, and abdominal pain)

          -  Documented evidence of no mechanical obstruction

          -  Delayed gastric emptying as demonstrated by gastric scintigraphy or breath test

        Exclusion Criteria:

          -  Uncontrolled diabetes (defined as HgbA1c &gt; 10%)

          -  Severe postural symptoms or evidence of unexplained recurrent dizziness

          -  Participant has received and tolerated domperidone and showed no notable symptomatic
             improvement in gastroparesis symptoms

          -  Participant has had endoscopic pyloric injections of botulinum toxin within the 6
             months prior to the Screening Visit.

          -  Participant engages in daily recreational use of marijuana

          -  Prolactin levels &gt; 2 x ULN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Wax, MD</last_name>
    <role>Study Director</role>
    <affiliation>Neurogastrx, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neurogastrx, Inc. Sponsor</last_name>
    <phone>781-730-4040</phone>
    <email>info@neurogastrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Synexus Clinical Research</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>205-870-8803</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Resaerch</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>480-775-1115</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Del Sol Research Management</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Preferred Research Partners</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oceana Gastroenterology Associates</name>
      <address>
        <city>Corona</city>
        <state>California</state>
        <zip>92879</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>951-220-4029</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prime Care Clinical Rsearch</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>949-364-1662</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diabetes Medical Center of California</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>818-368-4212</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Triwest Research Associates LLC</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coodinator</last_name>
      <phone>619-589-6888</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>707-542-1469</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>904-953-2955</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ENCORE Borland-Grover Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>904-386-7205</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Innovative Research of West Florida</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33770</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>208-346-8900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infinite Clinical Rsearch</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>786-220-9450</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atrium Health</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>704-355-4593</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baptist Diabetes Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33156</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>305-595-8252</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>International Research Associates LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33156</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>305-670-8830</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>PharmaSouth Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research Center</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>386-767-8800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Diseases, Inc. Research</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>888-737-7499</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Midtown West Medical PC</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>404-537-1281</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Gainesville</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>770-536-8109</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60602</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>312-494-2222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center LLC</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>812-471-4110</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Glen GI</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66217</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>919-830-4841</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aa Mrc Llc</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48504</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>810-237-1125</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Biomedical Research of America</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89123</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>702-898-2088</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Specialists</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>702-562-2420</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lovelace Respiratory Rsearch Institute</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>505-348-9500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11432</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>718-969-3005</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>330-252-1500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hometown Urgent Care and Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45215</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>937-912-4444</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>864-261-9563</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>864-811-9239</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions PC</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>731-431-5027</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avant Research Associates</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78704</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>303-921-9188</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>DM Clinical Research Solutions PC</name>
      <address>
        <city>Pearland</city>
        <state>Texas</state>
        <zip>77584</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-944-3610</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>210-614-7483</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>801-261-8930</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research - Intermountain Heart Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>801-542-8190</phone>
      <phone_ext>109</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Val Hansen MD</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>801-292-1422</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blue Ridge Medical Research</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24502</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>434-455-8670</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manassas Clinical Research Center</name>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <zip>20110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>703-330-1112</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metopimazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

